ArticleRMD open2024
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.
Article in RMD open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 25 citations in OpenAlex.
- From psoriatic plaque to synovium: decoding the skin-joint axis in psoriatic arthritis.Nature reviews. Rheumatology · 2026Review
- A Clinically Accessible Nomogram for Identifying Likely Psoriatic Arthritis Among Patients with Psoriasis: A Multicenter Cross-Sectional Study.Journal of clinical medicine · 2026Article
- Arthralgia and Ultrasound Characteristics of Subclinical Psoriatic Arthritis: A Cross-Sectional Study Based on the SPAWCH Cohort.The Journal of dermatology · 2026Article
- The Role of Musculoskeletal Ultrasound in Psoriatic Arthritis: From Preclinical Detection to Treatment Monitoring.Current rheumatology reports · 2026Review
- Does effective therapy of psoriasis prevent the development of psoriatic arthritis?EULAR rheumatology open · 2026Review
- Article
- Understanding the transition from psoriasis to psoriatic arthritis: the role of targeted therapy.EULAR rheumatology open · 2026Review
- Therapeutic Windows Across the Psoriatic Arthritis Spectrum.Rheumatology and therapy · 2026Review
- Transition From Psoriasis to Psoriatic Arthritis is Characterized by Distinct Alterations in Peripheral Blood Tc17, Th17, and CD4Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- The role of a multidisciplinary approach in the early and differential diagnosis of inflammatory bowel disease-related spondyloarthritis: insights from a cross-sectional study.Frontiers in medicine · 2026Article
- Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.Frontiers in immunology · 2026Review
- Clinical, hematologic, and inflammatory factors associated with psoriatic arthritis in a Chinese hospital-based study.Frontiers in immunology · 2026Article
- Navigating the Journey in Psoriatic Arthritis: Matching the Right Patient, the Right Drug, and the Right Time.Journal of clinical medicine · 2025Article
- Clinical and ultrasound features of a cohort of psoriasis patients without musculoskeletal symptoms: a prospective and multicentre study.Rheumatology (Oxford, England) · 2025Observational
- Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.Nature reviews. Rheumatology · 2025Review
- Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025Article
- Evaluation of the "Multivariable Psoriatic Arthritis Risk Estimation Tool" in a Cohort of Patients with Psoriasis: Preliminary Results of a Prospective Observational Study.Rheumatology and therapy · 2025Article
- Subclinical psoriatic arthritis and disease interception-where are we in 2024?Rheumatology (Oxford, England) · 2025Review
- Risk prediction model for psoriatic arthritis: NHANES data and multi-algorithm approach.Clinical rheumatology · 2025Article
- Skin and Nail Predictors of Psoriatic Arthritis Development: A Holistic Overview Integrating Epidemiological and Physiopathological Data.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSubjects with subclinical psoriatic arthritis (PsA), defined as the presence of arthralgia in psoriasis (PsO), are at higher risk of PsA but scant real-world data exist. Our aims were to (1) estimate the probability of PsA development in subclinical PsA, (2) characterise subclinical PsA symptoms and (3) determine the clinical patterns at PsA diagnosis.
methodsPatients with PsO, mainly subclinical PsA, were evaluated longitudinally in two European cohorts. The key outcome was new-onset PsA. Musculoskeletal symptoms including inflammatory and non-inflammatory symptoms before PsA diagnosis were collected. Occurrence of PsA was analysed with survival analysis and cumulative incidence functions (CIFs).
results384 patients with PsO were included with a mean follow-up of 33.0 (±20.9) months. 311 of 384 (80.9%) had subclinical PsA with a PsA incidence rate of 7.7 per 100 patient-years. Subclinical PsA displayed a higher risk of PsA development compared with PsO (HR=11.7 (95% CI 1.57 to 86.7), p=0.016). The probability of new-onset PsA estimated by the CIF was 9.4% (95% CI 4.7% to 10.6%) at month 12 and 22.7% (95% CI 17.2% to 28.6%) at month 36. 58.9% of cases reported inflammatory symptoms in the months immediately prior to PsA diagnosis but prior non-inflammatory symptoms were evident in 83.9% prior to PsA diagnosis. Peripheral joint swelling was the predominant PsA presentation pattern (82.1%).
conclusionsThe probability of PsA development among subclinical PsA was relatively high, emphasising the importance of emergent musculoskeletal symptoms when aiming for PsA prevention. Joint swelling was the dominant feature in new-onset PsA, likely reflecting clinical confidence in recognising joint swelling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.